Cellectis (CLLS) Change in Receivables (2015 - 2026)
Cellectis (CLLS) posted quarterly Change in Receivables of $7.9 million for Q1 2026, up 3550.0% year-over-year from $217397.3 in Q1 2025, and up 116.45% quarter-over-quarter from $3.7 million in Q3 2025.
Cellectis (CLLS) Change in Receivables (2015 - 2026) Analysis & Trends
Cellectis' Change in Receivables history runs 12 years deep, the most recent figure standing at $7.9 million for Q1 2026.
- In Q1 2026, Change in Receivables rose 3550.0% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $9.5 million (down 85.59% YoY), while the FY2024 annual figure was $52.6 million, up 2235.52% from the prior year.
- Change in Receivables for Q1 2026 stood at $7.9 million, up from $3.7 million in the prior quarter.
- The five-year high for Change in Receivables was $61.4 million in Q2 2024, with the low at -$13.5 million in Q1 2024.
- The 5-year median for Change in Receivables is $171500.0 (2022), against an average of $3.8 million.
- The sharpest annual moves came in 2023 and 2026: Change in Receivables sank 3769.7% in 2023, then surged 3550.0% in 2026.
- Cellectis' Change in Receivables stood at $578000.0 in 2022, then surged by 203.29% to $1.8 million in 2023, then jumped by 144.78% to $4.3 million in 2024, then decreased by 14.57% to $3.7 million in 2025, then surged by 116.45% to $7.9 million in 2026.
- Business Quant data shows CLLS's Change in Receivables at $7.9 million in Q1 2026, $3.7 million in Q3 2025, and -$1.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 7.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.94 Mn |
| Mar 31, 2026 | 7.94 Mn |
| Sep 30, 2025 | 3.67 Mn |
| Sep 30, 2025 | 3.67 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Mar 31, 2025 | -230,000.00 |
| Mar 31, 2025 | -230,000.00 |
| Dec 31, 2024 | 4.29 Mn |
| Dec 31, 2024 | 4.29 Mn |
| Sep 30, 2024 | 376,000.00 |
| Sep 30, 2024 | 376,000.00 |
| Jun 30, 2024 | 61.39 Mn |
| Jun 30, 2024 | 61.39 Mn |
| Mar 31, 2024 | -13.46 Mn |
| Mar 31, 2024 | -13.46 Mn |
| Dec 31, 2023 | 1.75 Mn |
| Dec 31, 2023 | 1.75 Mn |
| Sep 30, 2023 | -497,000.00 |
| Sep 30, 2023 | -497,000.00 |